• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小 RNA 在卵巢癌发病机制中的作用及其潜在的临床意义。

Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications.

机构信息

Unit of Molecular Therapies, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

出版信息

Int J Biochem Cell Biol. 2010 Aug;42(8):1262-72. doi: 10.1016/j.biocel.2009.12.017. Epub 2009 Dec 24.

DOI:10.1016/j.biocel.2009.12.017
PMID:20035894
Abstract

Despite important improvements over the past two decades, the overall cure rate of epithelial ovarian cancer (EOC) remains only approximately 30%. Although much has been learned about the proteins and pathways involved in early events of malignant transformation and drug resistance, a major challenge still remaining is the identification of markers for early diagnosis and prediction of response to chemotherapy. Recently, it has become clear that alterations in the expression of microRNAs (miRNAs) contribute to the pathogenesis and progression of several human malignancies. In this review we discuss current data concerning the accumulating evidence of the role of miRNAs in EOC pathogenesis and tumor characterization; their dysregulated expression in EOC; and their still undefined role in diagnosis, prognosis and prediction of response to therapy. The most frequently deregulated miRNAs are members of the let-7 and miR-200 families, the latter involved in epithelial-to-mesenchymal transition (EMT). EMT is part of normal ovarian surface epithelium physiology, being the key regulator of the post-ovulatory repair process, and failure to undergo EMT may be one of the events leading to transformation. A general down-modulation of miRNA expression is observed in EOC compared to normal tissue. However, a clear consensus on the miRNA signatures associated with prognosis or prediction of response to therapy has not yet been reached.

摘要

尽管在过去的二十年中取得了重要进展,但上皮性卵巢癌 (EOC) 的总体治愈率仍仅约为 30%。尽管已经了解了许多涉及恶性转化和耐药性早期事件的蛋白质和途径,但仍然存在一个主要挑战,即确定用于早期诊断和预测化疗反应的标志物。最近,已经清楚的是,miRNAs(miRNA)表达的改变有助于几种人类恶性肿瘤的发病机制和进展。在这篇综述中,我们讨论了 miRNA 在 EOC 发病机制和肿瘤特征中的作用的累积证据;它们在 EOC 中的失调表达;以及它们在诊断、预后和预测治疗反应中的作用仍未定义。最常失调的 miRNA 是 let-7 和 miR-200 家族的成员,后者参与上皮间质转化 (EMT)。EMT 是正常卵巢表面上皮生理学的一部分,是排卵后修复过程的关键调节剂,而不能进行 EMT 可能是导致转化的事件之一。与正常组织相比,EOC 中 miRNA 表达普遍下调。然而,尚未就与预后或预测治疗反应相关的 miRNA 特征达成明确共识。

相似文献

1
Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications.微小 RNA 在卵巢癌发病机制中的作用及其潜在的临床意义。
Int J Biochem Cell Biol. 2010 Aug;42(8):1262-72. doi: 10.1016/j.biocel.2009.12.017. Epub 2009 Dec 24.
2
MicroRNAs in ovarian cancer biology and therapy resistance.微小 RNA 在卵巢癌生物学和治疗耐药中的作用。
Int J Biochem Cell Biol. 2010 Aug;42(8):1282-90. doi: 10.1016/j.biocel.2010.01.014. Epub 2010 Jan 18.
3
Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics.卵巢癌中上皮-间质转化相关的微小RNA,重点关注miR-200家族:在卵巢癌治疗中的预后价值和潜在作用
Cancer Lett. 2014 Sep 1;351(2):173-81. doi: 10.1016/j.canlet.2014.05.022. Epub 2014 Jun 18.
4
Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression.Dicer 在卵巢癌中的表达与预后的关系——与全球 miRNA 变化和雌激素受体表达的关系。
J Pathol. 2010 Feb;220(3):382-91. doi: 10.1002/path.2658.
5
miRNAs as molecular biomarkers of cancer.miRNAs 作为癌症的分子生物标志物。
Expert Rev Mol Diagn. 2010 May;10(4):435-44. doi: 10.1586/erm.10.27.
6
Role of microRNAs in drug-resistant ovarian cancer cells.微小RNA在耐药性卵巢癌细胞中的作用。
Gynecol Oncol. 2008 Dec;111(3):478-86. doi: 10.1016/j.ygyno.2008.08.017. Epub 2008 Sep 26.
7
Down-regulation of dicer expression in ovarian cancer tissues.卵巢癌组织中 dicer 表达下调。
Clin Biochem. 2010 Feb;43(3):324-7. doi: 10.1016/j.clinbiochem.2009.09.014. Epub 2009 Sep 25.
8
Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis.微小 RNA 的差异表达谱及其在肾细胞癌发病机制中的潜在作用。
Clin Biochem. 2010 Jan;43(1-2):150-8. doi: 10.1016/j.clinbiochem.2009.07.020. Epub 2009 Jul 29.
9
Micromarkers: miRNAs in cancer diagnosis and prognosis.微标志物:miRNAs 在癌症诊断和预后中的应用。
Expert Rev Mol Diagn. 2010 Apr;10(3):297-308. doi: 10.1586/erm.10.11.
10
MicroRNAs as prognostic markers in ovarian cancer.微小RNA作为卵巢癌的预后标志物
Mol Cell Endocrinol. 2014 Jun 5;390(1-2):73-84. doi: 10.1016/j.mce.2014.03.006. Epub 2014 Apr 18.

引用本文的文献

1
Function of microRNA‑124 in the pathogenesis of cancer (Review).微小 RNA-124 在癌症发病机制中的功能(综述)。
Int J Oncol. 2024 Jan;64(1). doi: 10.3892/ijo.2023.5594. Epub 2023 Dec 1.
2
Combination microRNA-based cellular reprogramming with paclitaxel enhances therapeutic efficacy in a relapsed and multidrug-resistant model of epithelial ovarian cancer.基于微小RNA的细胞重编程与紫杉醇联合应用可增强复发性和多药耐药性上皮性卵巢癌模型的治疗效果。
Mol Ther Oncolytics. 2022 Mar 15;25:57-68. doi: 10.1016/j.omto.2022.03.005. eCollection 2022 Jun 16.
3
Long noncoding RNA DATOC-1 that associate with DICER promotes development in epithelial ovarian cancer by upregulating miR-7 expression.
与DICER相关的长链非编码RNA DATOC-1通过上调miR-7的表达促进上皮性卵巢癌的发展。
Transl Cancer Res. 2021 May;10(5):2379-2388. doi: 10.21037/tcr-20-189.
4
A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.一种新型靶向共递纳米系统,通过多药耐药逆转和 mTOR 介导的信号通路增强卵巢癌治疗。
J Nanobiotechnology. 2021 Dec 23;19(1):444. doi: 10.1186/s12951-021-01139-1.
5
The lncRNA 'UCA1' modulates the response to chemotherapy of ovarian cancer through direct binding to miR-27a-5p and control of UBE2N levels.长链非编码 RNA 'UCA1' 通过直接结合 miR-27a-5p 并控制 UBE2N 水平来调节卵巢癌对化疗的反应。
Mol Oncol. 2021 Dec;15(12):3659-3678. doi: 10.1002/1878-0261.13045. Epub 2021 Jul 13.
6
MicroRNA-765 sensitizes osteosarcoma cells to cisplatin via downregulating APE1 expression.微小RNA-765通过下调脱嘌呤/脱嘧啶核酸内切酶1(APE1)的表达使骨肉瘤细胞对顺铂敏感。
Onco Targets Ther. 2019 Sep 3;12:7203-7214. doi: 10.2147/OTT.S194800. eCollection 2019.
7
MicroRNA-19b promotes the migration and invasion of ovarian cancer cells by inhibiting the PTEN/AKT signaling pathway.微小RNA-19b通过抑制PTEN/AKT信号通路促进卵巢癌细胞的迁移和侵袭。
Oncol Lett. 2018 Jul;16(1):559-565. doi: 10.3892/ol.2018.8695. Epub 2018 May 10.
8
Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.卵巢癌上皮-间质表型可塑性的复杂决定因素
Cancers (Basel). 2017 Aug 9;9(8):104. doi: 10.3390/cancers9080104.
9
MicroRNA-216a promotes the metastasis and epithelial-mesenchymal transition of ovarian cancer by suppressing the PTEN/AKT pathway.微小RNA-216a通过抑制PTEN/AKT通路促进卵巢癌的转移和上皮-间质转化。
Onco Targets Ther. 2017 May 23;10:2701-2709. doi: 10.2147/OTT.S114318. eCollection 2017.
10
MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.微小RNA-520g通过抑制DAPK2促进上皮性卵巢癌进展和化疗耐药。
Oncotarget. 2016 May 3;7(18):26516-34. doi: 10.18632/oncotarget.8530.